Menu
 
Research menu
Jump to menu

Publications:  Dr Patrick Kennedy

Khakpoor A, Ni Y, Chen A, Ho ZZ, Oei V, Yang N, Giri R, Chow JX et al.(2019). Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection. J Virol vol. 93, (4)
10.1128/JVI.01457-18
Gill US, Kennedy PTF(2019). The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics. J Viral Hepat vol. 26, (1) 4-15.
10.1111/jvh.13040
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54283
KENNEDY P, HANSI N, Bertoletti A, Otano I(2018). Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.
10.1016/j.ymthe.2018.08.013
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55510
KENNEDY PATRICK(2018). PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. Journal of Clinical Investigation vol. 128, (10) 4573-4587.
10.1172/JCI121957
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55509
Foxler DE, Bridge KS, Foster JG, Grevitt P, Curry S, Shah KM, Davidson KM, Nagano A et al.(2018). A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia. EMBO Mol Med
10.15252/emmm.201708304
https://qmro.qmul.ac.uk/xmlui/handle/123456789/42128
Koffas A, Dolman GE, Kennedy PT(2018). Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clin Med (Lond) vol. 18, (3) 212-218.
10.7861/clinmedicine.18-3-212
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53577
Dolman GE, Koffas A, Mason WS, Kennedy PT(2018). Why, who and when to start treatment for chronic hepatitis B infection. Curr Opin Virol vol. 30, 39-47.
10.1016/j.coviro.2018.03.006
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54780
Bertoletti A, Kennedy PTF, Durantel D(2018). HBV infection and HCC: the 'dangerous liaisons'. Gut vol. 67, (5) 787-788.
10.1136/gutjnl-2017-315528
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31845
Gill US, Pallett LJ, Kennedy PTF, Maini MK(2018). Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. Gut vol. 67, (4) 767-775.
10.1136/gutjnl-2017-314873
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32130
KENNEDY P(2018). Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation vol. 128, (2) 668-681.
10.1172/JCI92812
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55629
KENNEDY P(2018). A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B. Annals of Gastroenterology vol. 31, 1-20.
10.20524/aog.2018.0300
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55524
KENNEDY P(2018). Circulating and intrahepatic antiviral B cells are defective in hepatitis B. Circulating and intrahepatic antiviral B cells are defective in hepatitis B.
10.1172/JCI121960
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55523
KENNEDY PATRICK(2018). Fine needle aspirates comprehensively sample intrahepatic immunity. Fine needle aspirates comprehensively sample intrahepatic immunity
10.1136/gutjnl-2018-317071
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55511
KENNEDY PATRICK(2017). Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity. Journal of Hepatology vol. 67, (4) 687-699.
10.1016/j.jhep.2017.05.025
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32139
Gill US, Hansi NK, Le Bert N, Kunasegaran K, Tan D, Dolman GE, Payaniandy L, Tong W et al. (2017). HBV-specific T cell immunity in inactive carrier patients is independent of Hepatitis B surface antigen load. HEPATOLOGY. vol. 66, 787A-788A.
Gill US, Le Bert N, Kunasegaran K, Khakpoor A, Hansi NK, Tan D, Rivino L, Singh HD et al. (2017). Transcriptome profiles of NK and T cells regulating immune control in chronic hepatitis B, proximate to patients treated with Pegylated Interferon alpha-Nucleos(t)ide analogue (NA) sequential therapy compared to de novo NA therapy. HEPATOLOGY. vol. 66, 70A-70A.
Gill US, Kennedy PTF(2017). Current therapeutic approaches for HBV infected patients. J Hepatol vol. 67, (2) 412-414.
10.1016/j.jhep.2017.04.015
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36429
Salpini R, Piermatteo L, Gill U, Battisti A, Stazi F, Guenci T, Giannella S, Serafini V et al.(2017). Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0. Med Microbiol Immunol vol. 206, (4) 295-299.
10.1007/s00430-017-0504-3
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31843
Singh HD, Otano I, Rombouts K, Singh KP, Peppa D, Gill US, Böttcher K, Kennedy PTF et al.(2017). TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Sci Rep vol. 7, (1)
10.1038/s41598-017-05845-5
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32137
Pallett LJ, Davies J, Colbeck EJ, Robertson F, Hansi N, Easom NJW, Burton AR, Stegmann KA et al.(2017). IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. J Exp Med vol. 214, (6) 1567-1580.
10.1084/jem.20162115
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32127
Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS(2017). Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. Viruses vol. 9, (5)
10.3390/v9050096
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32129
Kennedy PTF, Bertoletti A, Mason WS(2017). Reply. Gastroenterology vol. 152, (5) 1246-1247.
10.1053/j.gastro.2017.03.002
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36430
Gill US, Peppa D, Micco L, Singh HD, Le Bert N, Rivino L, Kunasegaran K, Tan D et al. (2017). Effect of in-vivo hepatitis B viral load suppression after interferon exposure on natural killer and T-cell responsiveness. vol. 389, pp. 39-39.
Salpini R, Battisti A, Anastasiou O, Gill U, Colagrossi L, Bertoli A, Fabeni L, Fini V et al. (2017). In HBeAg-negative chronic HBV infection, HBsAg levels profoundly differ among HBV-genotypes and can be affected by the extent of HBsAg variability: Can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?. DIGESTIVE AND LIVER DISEASE. vol. 49, E45-E45.
10.1016/j.dld.2017.01.093
Salpini R, Colagrossi L, Battisti A, Hansi N, Perno CF, Gill US, Kennedy PTF, Svicher V (2017). Peripheral and intrahepatic virological phenotyping in HBeAg negative Chronic Hepatitis B to evaluate risk of disease progression and HCC in the "grey-zone" viral load cohort: Can grey-zone patients be candidate to treatment?. DIGESTIVE AND LIVER DISEASE. vol. 49, E7-E7.
10.1016/j.dld.2017.01.017
Salpini R, Battisti A, Anastasiou O, Gill U, Colagrossi L, Bertoli A, Fabeni L, Fini V et al. (2017). In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?. JOURNAL OF HEPATOLOGY. vol. 66, S470-S470.
10.1016/S0168-8278(17)31327-2
Salimzadeh L, Bert NL, Gill US, Kennedy PT, Samuel D, Novikov N, Pflanz S, Frey CR et al. (2017). Modifications of virus-specific and total B cell populations by hepatitis B virus infection. JOURNAL OF HEPATOLOGY. vol. 66, S28-S29.
10.1016/S0168-8278(17)30320-3
Le Bert N, Rivino L, Gill US, Cheng Y, Kunasegaran K, Tan DZ, Becht E, Hansi NK et al. (2017). PD-1+CD8+T cells as immunological biomarkers for the safe discontinuation of anti-viral therapy in chronic hepatitis B. JOURNAL OF HEPATOLOGY. vol. 66, S687-S687.
10.1016/S0168-8278(17)31847-0
Svicher V, Salpini R, Colagrossi L, Battisti A, Piermatteo L, Hansi N, Perno CF, Gill US et al. (2017). Peripheral and intrahepatic virological phenotyping in eAg negative chronic hepatitis B to evaluate risk of disease progression and hepatocellular carcinoma in the "grey-zone" viral load cohort. JOURNAL OF HEPATOLOGY. vol. 66, S701-S701.
10.1016/S0168-8278(17)31880-9
KENNEDY PATRICK(2017). Reply. Gastroenterology vol. 152, (5) 1246-1247.
10.1053/j.gastro.2017.03.002
https://qmro.qmul.ac.uk/xmlui/handle/123456789/57254
KENNEDY P(2017). T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System. T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System
10.4049/jimmunol.1601313
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32134
Gill US, Bert NL, Kunasegaran K, Khakpoor A, Hansi N, Tan D, Rivino L, Singh HD et al. (2017). Transcriptome profiles of NK and T cells associated with immune control in chronic hepatitis B patients treated with pegylated interferon alpha-nucleos(t)ide analogue sequential therapy. JOURNAL OF HEPATOLOGY. vol. 66, S542-S542.
10.1016/S0168-8278(17)31491-5
Huang W-C, Easom NJ, Tang X-Z, Gill US, Singh H, Robertson F, Chang C, Trowsdale J et al.(2016). T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System. J Immunol vol. 198, (3) 1172-1182.
10.4049/jimmunol.1601313
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32134
Svicher V, Salpini R, Gill US, Colagrossi L, Hansi NK, Perno CF, Kennedy PT (2016). Peripheral and intrahepatic virological phenotyping in eAg negative Chronic Hepatitis B underlines the limitations of current treatment thresholds in low to moderate viraemic patients. HEPATOLOGY. vol. 64, 308A-308A.
Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PTF(2016). Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. PLOS Pathogens vol. 12, (8) e1005788-e1005788.
10.1371/journal.ppat.1005788
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15242
Schurich A, Pallett LJ, Jajbhay D, Wijngaarden J, Otano I, GIll US, Hansi N, Kennedy PT et al.(2016). Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Reports vol. 16, (5) 1243-1252.
10.1016/j.celrep.2016.06.078
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13465
Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, Hong ML, Naik S et al.(2016). HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. Gastroenterology
10.1053/j.gastro.2016.07.012
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15184
Hansi N, Troke P, Gill US, Agarwal K, Aldersley M, Al-Shamma S, Brown A, Cobbold J et al. (2016). CHRONIC HEPATITIS B MANAGEMENT THE UK: A NATIONAL SURVEY OF CURRENT PRACTICE FOLLOWING NICE GUIDANCE. GUT. vol. 65, A271-A272.
10.1136/gutjnl-2016-312388.511
Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, Christophides T, Pallett LJ, Peppa D et al.(2016). CXCR6 marks a novel subset of T-betloEomeshi natural killer cells residing in human liver. Scientific Reports vol. 6, 26157-26157.
10.1038/srep26157
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15183
Chan HL-Y, Messinger D, Papatheodoridis GV, Cornberg M, Xie Q, Piratvisuth T, Ren H, Kennedy P et al. (2016). A GENOTYPE-SPECIFIC BASELINE SCORE TO PREDICT POST-TREATMENT RESPONSE TO PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS WITH HEPATITIS B VIRUS GENOTYPE B OR C INFECTION. JOURNAL OF HEPATOLOGY. vol. 64, S589-S590.
10.1016/S0168-8278(16)01085-0
Lampertico P, Messinger D, Cornberg M, Brunetto M, Petersen J, Kennedy P, Asselah T, Rothe V et al. (2016). A GENOTYPE-SPECIFIC BASELINE SCORE TO PREDICT RESPONSE AT 48 WEEKS POST-TREATMENT TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 64, S599-S600.
10.1016/S0168-8278(16)01106-5
Rivino L, Le Bert N, Gill U, Cheng Y, Kunasegaran K, Tan D, Koh S, Hansi N et al. (2016). AN IMMUNOLOGICAL BIOMARKER TO PREDICT HEPATIC FLARES UPON NUC THERAPY DISCONTINUATION IN CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 64, S164-S165.
10.1016/S0168-8278(16)01672-X
Le Bert N, Rivino L, Cheng Y, Tan D, Newell E, Arvey A, Kennedy P, Pflanz S et al. (2016). APPLICATION OF MASS CYTOMETRY TIME OF FLIGHT (CYTOF) FOR SYSTEMATIC CHARACTERIZATION OF PBMC PHENOTYPES ASSOCIATED WITH HBSAG SERUM LEVELS IN CHRONIC HBV PATIENTS. JOURNAL OF HEPATOLOGY. vol. 64, S393-S394.
10.1016/S0168-8278(16)00614-0
Gill US, Rivino L, Le Bert N, Kunasegaran K, Tan D, Koh S, Van den Berg M, Cheng Y et al. (2015). Characterisation of the immune profile in Chronic Hepatitis B, with CyTOF, to identify biomarkers of immune control following NUC therapy discontinuation. HEPATOLOGY. vol. 62, 294A-294A.
Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PT (2015). NK cell function is restored with sequential NUC therapy and correlates with treatment response in Chronic Hepatitis B. HEPATOLOGY. vol. 62, 1001A-1002A.
Hansi NK, Seipt CC, Gill US, Naik S, Tong W, Foster GR, Carey I, Kennedy PT (2015). Quantitative Hepatitis B surface antigen (qHBsAg) may define low-risk inactive carriers of CHB: Can this provide a framework for better management across all age-groups?. HEPATOLOGY. vol. 62, 976A-977A.
Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, T Kennedy P, Dusheiko G, Hill-Cawthorne G et al.(2015). Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom. Value Health vol. 18, (6) 800-809.
10.1016/j.jval.2015.05.007
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55748
Rivino L, Van Den Berg M, Gill US, Le Bert N, Koh S, Hansi NK, Newell E, Foster GR et al. (2015). CHARACTERISATION OF THE IMMUNE PROFILE IN CHRONIC HEPATITIS B PATIENTS FOLLOWING NUCLEOS (T)IDE DISCONTINUATION BY CYTOF MASS CYTOMETRY. GUT. vol. 64, A106-A107.
10.1136/gutjnl-2015-309861.218
Hansi N, Gill US, Banerjee M, Naik S, Tong W, Foster GR, Carey I, Kennedy PT (2015). DEFINING THE LOW-RISK INACTIVE CARRIER IN CHRONIC HEPATITIS B WITH QHBSAG: DO THE SAME RULES APPLY IN CHILDREN AND YOUNG ADULTS?. GUT. vol. 64, A108-A109.
10.1136/gutjnl-2015-309861.222
Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PTF (2015). FUNCTIONAL IMMUNE RESTORATION CORRELATES WITH HBSAG DECLINE AND MAY PREDICT TREATMENT RESPONSE ON SEQUENTIAL NUC THERAPY IN CHB. GUT. vol. 64, A113-A113.
10.1136/gutjnl-2015-309861.231
Hansi N, Gill US, Banerjee M, Naik S, Tong W, Foster GR, Carey I, Kennedy PT (2015). IDENTIFYING TRUE IMMUNE-TOLERANT DISEASE IN CHILDREN AND YOUNG ADULTS WITH CHB USING QUANTIFIED HEPATITIS B SURFACE ANTIGEN LEVELS. GUT. vol. 64, A108-A108.
10.1136/gutjnl-2015-309861.221
Pallett LJ, Gill US, Quaglia A, Sinclair LV, Jover-Cobos M, Schurich A, Singh KP, Thomas N et al.(2015). Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat Med vol. 21, (6) 591-600.
10.1038/nm.3856
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55383
Gill US, Hansi NK, Payaniandy L, Schulz J, Payaniandy D, Alazawi W, Dearden J, Kallis YN et al. (2015). SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON PROVIDES A GREATER DECLINE IN HBSAG AND POTENTIALLY OFFERS A TREATMENT ADVANTAGE OVER CURRENT THERAPIES. GUT. vol. 64, A113-A113.
10.1136/gutjnl-2015-309861.232
El Bouzidi K, Elamin W, Kranzer K, Irish DN, Ferns B, Kennedy P, Rosenberg W, Dusheiko G et al.(2015). Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. J Clin Virol vol. 66, 33-37.
10.1016/j.jcv.2015.02.011
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31963
Bertoletti A, Kennedy PT(2015). The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol vol. 12, (3) 258-263.
10.1038/cmi.2014.79
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31841
Rivino L, Van Den Berg M, Le Bert N, Koh S, Gill US, Hansi NK, Foster GR, Bertoletti A et al. (2015). CHARACTERISATION OF THE IMMUNE PROFILES OF CHRONIC HEPATITIS B PATIENTS FOLLOWING NUC DISCONTINUATION BY CyTOF MASS CYTOMETRY. JOURNAL OF HEPATOLOGY. vol. 62, S491-S491.
10.1016/S0168-8278(15)30682-6
Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PT (2015). FUNCTIONAL IMMUNE RESTORATION CORRELATES WITH HBsAg DECLINE AND MAY PREDICT TREATMENT RESPONSE ON SEQUENTIAL NUC THERAPY IN CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 62, S496-S496.
10.1016/S0168-8278(15)30693-0
Huang W-C, Peppa D, Easom N, Tang X-Z, Singh H, Fusai G, Rosenberg W, Ghosh I et al. (2015). NKG2D-DEPENDENT CROSS-TALK BETWEEN NK CELLS AND CD4 T CELLS IN CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 62, S493-S493.
10.1016/S0168-8278(15)30686-3
Gill US, Kennedy PT(2015). New insights in the management of chronic hepatitis B. Clin Med (Lond) vol. 15, (2) 191-196.
10.7861/clinmedicine.15-2-191
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31837
Mathew S, Petrova M, Hendy J, de Lusignan S, Zamani J, Tiwari R, Nicholls M, Kennedy P et al. (2015). PERCEPTIONS OF VIRAL HEPATITIS TESTING IN MIGRANT COMMUNITIES AND THE PRIMARY CARE PHYSICIANS THAT SERVE THEM. JOURNAL OF HEPATOLOGY. vol. 62, S830-S830.
10.1016/S0168-8278(15)31455-0
Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJW, Barr DA, Kallis YN, Marley RTC et al.(2015). Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?. J Infect Dis vol. 211, (3) 374-382.
10.1093/infdis/jiu471
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36431
Pallett L, Gill U, Jover-Cobos M, Schurich A, Singh K, Thomas N, Das A, Chen A et al.(2014). Arginase-dependent metabolic regulation of hepatic immunopathology by myeloid-derived suppressor cells. IMMUNOLOGY vol. 143, 154-154.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/17996
Gill US, Kennedy PTF(2014). Chronic hepatitis B virus in young adults: the need for new approaches to management. Expert Rev Anti Infect Ther vol. 12, (9) 1045-1053.
10.1586/14787210.2014.940899
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36432
Jo J, Tan AT, Ussher JE, Sandalova E, Tang X-Z, Tan-Garcia A, To N, Hong M et al.(2014). Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog vol. 10, (6)
10.1371/journal.ppat.1004210
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13877
Kennedy PTF, Gill US, Bertoletti A, Mason WS (2014). CLONAL HEPATOCYTE REPOPULATION IN THE YOUNG ADULT HBV INFECTED LIVER CHALLENGES THE CONCEPT OF A GENERIC IMMUNE TOLERANT DISEASE PHASE. JOURNAL OF HEPATOLOGY. vol. 60, S43-S43.
10.1016/S0168-8278(14)60108-2
Lubowiecki M, Pallmer K, Jajbhay D, Pallett LJ, Gill U, Kennedy PT, Maini M, Schurich A (2014). CO-INHIBITORY RECEPTOR LAG-3 POSITIVE CD8 T CELLS PRODUCE IMMUNOSUPPRESSIVE TGF-beta IN CHRONIC HBV. JOURNAL OF HEPATOLOGY. vol. 60, S118-S119.
10.1016/S0168-8278(14)60321-4
Pallett LJ, Haniffa M, Schurich A, Gill U, Davies N, Jover-Cobos M, Das A, Gilson R et al. (2014). MYELOID-DERIVED SUPPRESSOR CELLS MEDIATE IMMUNOTOLERANCE IN CHRONIC HEPATITIS B (CHB) THROUGH ARGININE DEPRIVATION. JOURNAL OF HEPATOLOGY. vol. 60, S109-S109.
10.1016/S0168-8278(14)60294-4
Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PTF (2014). SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON-ALPHA EXPOSURE RESTORES INNATE IMMUNE RESPONSES CONFERRING A TREATMENT ADVANTAGE OVER NUC MONOTHERAPY IN CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 60, S116-S116.
10.1016/S0168-8278(14)60314-7
Huang W-C, Peppa D, Easom N, Tan X-Z, Chang C, Trowsdale J, Gill U, Kennedy P et al. (2014). THE EXPRESSION OF NKG2D-LIGANDS BY ACTIVATED CD4 T CELLS RENDERS THEM SUSCEPTIBLE TO NK CELL REGULATION IN CHRONIC HEPATITIS B (CHB). JOURNAL OF HEPATOLOGY. vol. 60, S111-S111.
10.1016/S0168-8278(14)60299-3
Kennedy PT, Gill US, Chen A, Litwin S, Bertoletti A, Mason W (2014). Clonal Hepatocyte expansion in the young adult HBV infected liver is at odds with the concept of a generic immune tolerant disease phase: can additional clinical parameters distinguish disease phase?. HEPATOLOGY. vol. 60, 1032A-1033A.
Gill US, Peppa D, Singh HD, Micco L, Foster GR, Maini MK, Kennedy PT (2014). Functional innate immune responses are restored with sequential NUC therapy following Pegylated Interferon-Alpha exposure and not with NUC monotherapy in Chronic Hepatitis B. HEPATOLOGY. vol. 60, 1020A-1021A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7014
Hansi NK, Gill US, Banerjee A, Surendraraj N, Patel C, Naik S, Foster GR, Kennedy PT (2014). High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true 'immune-tolerance' in children and young adults with Chronic Hepatitis B. HEPATOLOGY. vol. 60, 985A-986A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7139
Lubowiecki M, Pallmer K, Jajbhay D, Pallett LJ, Gill U, Kennedy PT, Maini MK, Schurich A (2013). Co-inhibitory receptor LAG-3 positive CD8 T cells produce immunosuppressive TGF-beta in chronic HBV. IMMUNOLOGY. vol. 140, 145-145.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/17997
Pallett LJ, Haniffa M, Jover-Cobos M, Schurich A, Das A, Gill U, Davies N, Ghosh I et al. (2013). Expansion of arginase-expressing myeloid-derived suppressor cells in hepatotropic viral infections. IMMUNOLOGY. vol. 140, 97-97.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9841
Gill US, Patel C, Naik S, Dearden J, Kallis YN, Kooner P, Marley R, Aleong J-AC et al. (2013). Collagen proportionate area but not Ishak fibrosis stage on liver biopsy correlates with age in Chronic Hepatitis B infected young adults. HEPATOLOGY. vol. 58, 427A-428A.
Chen A, Gill US, Ikin CR, Aleong J-AC, Foster GR, Kennedy PT (2013). Differential Hepatitis B virus core nuclear/cytoplasmic staining is a marker of longevity of chronic infection but not disease phase. HEPATOLOGY. vol. 58, 423A-424A.
Gill US, Peppa D, Micco L, Foster GR, Maini MK, Kennedy PT (2013). Sustained restoration of innate immune responses and sAg decline in sequential NUC therapy following failed Pegylated-Interferon-alpha therapy in Chronic Hepatitis B. HEPATOLOGY. vol. 58, 416A-417A.
Gehring AJ, Haniffa M, Kennedy PT, Ho ZZ, Boni C, Shin A, Banu N, Chia A et al.(2013). Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. JOURNAL OF CLINICAL INVESTIGATION vol. 123, (9) 3766-3776.
10.1172/JCI66043
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55525
Gill US, Zissimopoulos A, Al-shamma S, Burke K, McPhail M, Barr D, Ross V, Kallis Y et al. (2013). FRAX SCORE IN THE ASSESSMENT OF BONE MINERAL DENSITY CHANGES IN TENOFOVIR TREATED CHRONIC HEPATITIS B PATIENTS. GUT. vol. 62, A190-A190.
10.1136/gutjnl-2013-304907.432
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9836
Gill US, Payaniandy L, Schulz J, Payaniandy D, Ross V, Kallis Y, Kooner P, Marley R et al. (2013). SEQUENTIAL ORAL ANTI-VIRAL THERAPY FOLLOWING PEGYLATED-INTERFERON-ALPHA FAILURE SIGNIFICANTLY INCREASES HBSAG DECLINE. GUT. vol. 62, A189-A190.
10.1136/gutjnl-2013-304907.431
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9839
Alazawi W, Abeysekera K, Dearden J, Glynn M, Kallis Y, Kennedy P, Marley R, Foster GR et al. (2013). IMPLEMENTING EASL & AASLD GUIDELINES FOR HEPATOCELLULAR CARCINOMA SCREENING IS COST-EFFECTIVE IN LONDON'S ETHNICALLY DIVERSE POPULATION. JOURNAL OF HEPATOLOGY. vol. 58, S397-S397.
10.1016/S0168-8278(13)60966-6
Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross VA, Kallis YN, Kooner P, Marley RTC et al. (2013). INDUCTION MAINTENANCE THERAPY IN CHRONIC HEPATITIS B; STEP-DOWN FROM COMBINATION LAMIVUDINE AND TENOFOVIR TO LAMIVUDINE MONOTHERAPY - A POTENTIAL NEW TREATMENT STRATEGY. JOURNAL OF HEPATOLOGY. vol. 58, S302-S302.
10.1016/S0168-8278(13)60748-5
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9891
Chen A, Schurich A, Aleong J-AC, Trivedi K, Gill U, Peppa D, Kennedy P, Bertoletti A et al. (2013). PROBING HEPATIC ANTIGEN PRESENTATION IN PATIENTS WITH CHRONIC HBV INFECTION. JOURNAL OF HEPATOLOGY. vol. 58, S136-S136.
10.1016/S0168-8278(13)60327-X
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9890
Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S et al.(2013). The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells. PLOS PATHOGENS vol. 9, (3) Article ARTN e1003208,
10.1371/journal.ppat.1003208
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13876
Peppa D, Gill US, Reynolds G, Easom NJW, Pallett LJ, Schurich A, Micco L, Nebbia G et al.(2013). Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. JOURNAL OF EXPERIMENTAL MEDICINE vol. 210, (1) 99-114.
10.1084/jem.20121172
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13875
Ji C, Sastry KSR, Tiefenthaler G, Cano J, Tang T, Ho ZZ, Teoh D, Bohini S et al.(2012). Targeted Delivery of Interferon-alpha to Hepatitis B Virus-Infected Cells Using T-Cell Receptor-Like Antibodies. HEPATOLOGY vol. 56, (6) 2027-2038.
10.1002/hep.25875
Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y, Rosenberg W, Dusheiko G et al.(2012). Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection. PLOS ONE vol. 7, (10) Article ARTN e47648,
10.1371/journal.pone.0047648
https://qmro.qmul.ac.uk/xmlui/handle/123456789/5367
Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, Chen A, Blair P et al.(2012). IL-10-Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection. JOURNAL OF IMMUNOLOGY vol. 189, (8) 3925-3935.
10.4049/jimmunol.1103139
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9844
Patel C, Gill U, Alazawi W, Shaw P, Alstead EM, Kallis Y, Kooner P, Marley R et al. (2012). Benchmarking disease activity and progression in Chronic Hepatitis B infected young adults. HEPATOLOGY. vol. 56, 362A-362A.
Gill U, Zissimopoulos A, Al-Shamma S, Burke KB, Ross VA, Kallis Y, Kooner P, Marley R et al. (2012). FRAX score in the assessment of Bone Mineral Density changes in Tenofovir treated Chronic Hepatitis B patients: comparison with bone biochemistry and DEXA scanning. HEPATOLOGY. vol. 56, 201A-201A.
Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, Naik S, Foster GR et al.(2012). Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology vol. 143, (3) 637-645.
10.1053/j.gastro.2012.06.009
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31839
Gill US, Payaniandy L, Schulz J, Ross V, Kallis Y, Kooner P, Marley R, Ushiro-Lumb I et al.(2012). CAN A 3-MONTH "STOPPING RULE" FOR PEGYLATED-INTERFERON-alpha BE APPLIED TO A UK POPULATION OF CHRONIC HEPATITIS B INFECTED PATIENTS OF MIXED GENOTYPE?. GUT vol. 61, A145-A145.
10.1136/gutjnl-2012-302514b.175
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9889
Cunningham ME, Schulz J, Payaniandy L, Kallis Y, Kennedy P, Kooner P, Marley R, Foster GR(2012). EARLY EXPERIENCE WITH TELAPREVIR FOR PATIENTS WITH ADVANCED FIBROSIS OR CIRRHOSIS. GUT vol. 61, A141-A141.
10.1136/gutjnl-2012-302514b.166
Patel C, Gill US, Alazawi W, Shaw P, Alstead E, Kallis Y, Kooner P, Marley R et al.(2012). EVALUATION OF LIVER FIBROSIS IN YOUNG ADULT PATIENTS WITH CHRONIC HEPATITIS B VIRUS. GUT vol. 61, A133-A133.
10.1136/gutjnl-2012-302514b.148
Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross V, Kallis Y, Kooner P, Marley R et al.(2012). INDUCTION MAINTENANCE TREATMENT IN CHRONIC HEPATITIS B; STEP-DOWN FROM TENOFOVIR AND LAMIVUDINE TO LAMIVUDINE MONOTHERAPY IS EFFECTIVE. GUT vol. 61, A145-A145.
10.1136/gutjnl-2012-302514b.176
Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al.(2012). MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-alpha THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B. GUT vol. 61, A145-A146.
10.1136/gutjnl-2012-302514b.177
Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al. (2012). MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-APLHA THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 56, S175-S175.
10.1016/S0168-8278(12)60454-1
Liu M, Miao T, Zhu H, Symonds ALJ, Li L, Schurich A, Maini MK, Zhang J et al.(2012). IL-2-Engineered nano-APC Effectively Activates Viral Antigen-Mediated T Cell Responses from Chronic Hepatitis B Virus-Infected Patients. JOURNAL OF IMMUNOLOGY vol. 188, (3) 1534-1543.
10.4049/jimmunol.1102709
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31846
Kennedy P, Prasad PB, Boyer J(2012). Hepatobiliary sarcoidosis. Sarcoidosis,
Nebbia G, Peppa D, Schurich A, Khanna P, Singh H, Rosenberg W, Dusheiko G, Gilson R et al. (2011). Role of the TIM-3/Galectin-9 pathway in chronic hepatitis B infection. IMMUNOLOGY. vol. 135, 69-69.
Peppa D, Gill U, Micco L, Schurich A, Nebbia G, Singh H, Rosenberg W, Gilson R et al. (2011). Susceptibility of T cells to death ligand-mediated deletion in the liver of chronic hepatitis B virus (CHB) infected patients. IMMUNOLOGY. vol. 135, 60-60.
Gill U, Al-Shamma S, Burke KB, Ross VA, Marley R, Kooner P, Foster GR, Kennedy PT (2011). BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY. HEPATOLOGY. vol. 54, 1012A-1012A.
Kennedy PT, Sandalova E, Jo J, Gill U, Li L, Ushiro-Lumb I, Naik S, Foster GR et al. (2011). IMMUNOLOGICAL ANALYSIS AND CLINICAL PROFILE OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN THE YOUNGER PATIENT. HEPATOLOGY. vol. 54, 1092A-1093A.
Gill US, Al-Shamma S, Burke K, Ross V, Marley RTC, Kooner P, Foster GR, Kennedy PTF(2011). BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY. GUT vol. 60, A28-A28.
10.1136/gutjnl-2011-300857a.61
Kennedy PTF, Sandalova E, Jo J, Gill US, Li L, Ushiro-Lumb I, Naik S, Foster GR et al.(2011). IMMUNOLOGICAL ANALYSIS AND CLINICAL PROFILE OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN THE YOUNGER PATIENT. GUT vol. 60, A29-A29.
10.1136/gutjnl-2011-300857a.62
Glyn FJ, Gill U, Alazawi W, Ross V, Kooner P, Marley R, Foster G, Kennedy PT (2011). Efficacy of Combination Tenofovir Plus Lamivudine Versus Tenofovir Monotherapy in Patients With Chronic Hepatitis B Virus. GASTROENTEROLOGY. vol. 140, S455-S455.
Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, Nebbia G, Kennedy PTF et al.(2011). Role of the Coinhibitory Receptor Cytotoxic T Lymphocyte Antigen-4 on Apoptosis-Prone CD8 T Cells in Persistent Hepatitis B Virus Infection. HEPATOLOGY vol. 53, (5) 1494-1503.
10.1002/hep.24249
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31840
Gunawan AS, Gill U, Glyn FJ, Kooner P, Marley R, Ushiro-Lumb I, Foster G, Kennedy PT (2011). Utility of HBsAg Quantification in Developing an Individualised Approach to the Management of Chronic Hepatitis B Virus in Clinical Practice. GASTROENTEROLOGY. vol. 140, S458-S458.
Patel C, Gill US, Glyn F, Naik S, Foster GR, Kennedy PTF (2011). CHRONIC HBV INFECTION: ASSESSMENT AND MANAGEMENT OF DISEASE IN A YOUNG ADULT CLINIC. GUT. vol. 60,
10.1136/gut.2011.239301.487
Glyn F, Gill US, Alazawi W, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF (2011). EFFICACY OF COMBINATION TENOFOVIR PLUS LAMIVUDINE VERSUS TENOFOVIR MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS. GUT. vol. 60, A231-A231.
10.1136/gut.2011.239301.488
Gill US, Al-Shamma S, Burke K, Ross V, Marley R, Kooner P, Foster GR, Kennedy PTF (2011). FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT?. GUT. vol. 60,
10.1136/gut.2011.239301.486
Gill U, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF (2011). PEGYLATED INTERFERON A MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION. GUT. vol. 60, A232-A232.
10.1136/gut.2011.239301.490
Gunawan A, Gill US, Glyn F, Kooner P, Marley R, Ushiro-Lumb I, Foster GR, Kennedy PTF (2011). UTILITY OF HBSAG QUANTIFICATION IN DEVELOPING AN INDIVIDUALISED APPROACH TO THE MANAGEMENT OF CHRONIC HEPATITIS B VIRUS IN CLINICAL PRACTICE. GUT. vol. 60,
10.1136/gut.2011.239301.489
Schurich A, Khanna P, Lubowiecki M, Lopes AR, Peppa D, Micco L, Nebbia G, Singh H et al. (2011). ALTERING CO-INHIBITORY AND CO-STIMULATORY PATHWAYS TO RESTORE ANTI-VIRAL T CELL RESPONSES IN CHRONIC HBV INFECTION. JOURNAL OF HEPATOLOGY. vol. 54, S125-S125.
10.1016/S0168-8278(11)60311-5
Gill US, Al-Shamma S, Burke K, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF (2011). FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT?. JOURNAL OF HEPATOLOGY. vol. 54, S286-S286.
10.1016/S0168-8278(11)60715-0
Gill US, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF (2011). PEGYLATED INTERFERON ALPHA MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION. JOURNAL OF HEPATOLOGY. vol. 54, S32-S32.
10.1016/S0168-8278(11)60072-X
Ji C, Seetharama S, Tang T, Tei TC, Tiefenthaler G, Lopatin U, Sankuratri S, Ma H et al. (2011). TARGETED DELIVERY OF ANTI-VIRAL CYTOKINE TO HBV-INFECTED CELLS USING T CELL RECEPTOR-LIKE ANTIBODIES. JOURNAL OF HEPATOLOGY. vol. 54, S32-S33.
10.1016/S0168-8278(11)60074-3
Sastry KSR, Too CT, Kaur K, Gehring AJ, Low L, Javiad A, Pollicino T, Li L et al.(2011). Targeting Hepatitis B Virus-Infected Cells with a T-Cell Receptor-Like Antibody. J VIROL vol. 85, (5) 1935-1942.
10.1128/JVI.01990-10
Peppa D, Micco L, Javaid A, Kennedy PTF, Schurich A, Dunn C, Pallant C, Ellis G et al.(2010). Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection. PLOS PATHOG vol. 6, (12) Article e1001227,
10.1371/journal.ppat.1001227
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13878
Kennedy PTF, Zakaria N, Modawi SB, Papadopoulou AM, Murray-Lyon I, du Bois RM, Jervoise N Andreyev H, Devlin J(2006). Natural history of hepatic sarcoidosis and its response to treatment. Eur J Gastroenterol Hepatol vol. 18, (7) 721-726.
10.1097/01.meg.0000223911.85739.38
Zakaria N, Kennedy PTF, Mudawi S, Papadopoulou A, Murray-Lyon I, Dubois R, Devlin J, Andreyev HJN (2005). The natural history of hepatic sarcoid. GUT. vol. 54, A48-A48.
Schurich A, Pallett LP, Jajbhay D, Wijngaarden J, Otano I, Gill US, Hansi N, Kennedy PT et al.. Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Reports
10.1016/j.celrep.2016.06.078
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13465
Return to top